|
|
|
Volumn 273, Issue 7310, 2004, Pages 153-155
|
|
Why do therapeutic drug monitoring
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIKACIN;
AMINOGLYCOSIDE ANTIBIOTIC AGENT;
AMPHOTERICIN;
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
ANTIFUNGAL AGENT;
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
CYCLOSERINE;
CYCLOSPORIN;
DIGOXIN;
ETHAMBUTOL;
FLUCYTOSINE;
GENTAMICIN;
GLYCOPEPTIDE;
IMMUNOSUPPRESSIVE AGENT;
ISONIAZID;
ITRACONAZOLE;
NEUROLEPTIC AGENT;
PROTEINASE INHIBITOR;
PYRAZINAMIDE;
RIFABUTIN;
RIFAMPICIN;
STREPTOMYCIN;
TEICOPLANIN;
THEOPHYLLINE;
TUBERCULOSTATIC AGENT;
UNINDEXED DRUG;
VANCOMYCIN;
AREA UNDER THE CURVE;
ARTICLE;
ASTHMA;
CANCER;
DEPRESSION;
DOSE RESPONSE;
DOSE TIME EFFECT RELATION;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG DOSE REGIMEN;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG MONITORING;
DRUG SURVEILLANCE PROGRAM;
EPILEPSY;
GRAFT REJECTION;
HEART DISEASE;
HUMAN;
INFECTION;
INTERNATIONAL STANDARD UNIT;
MINIMUM INHIBITORY CONCENTRATION;
MYCOSIS;
NEPHROTOXICITY;
NEUROTOXICITY;
PHARMACOLOGICAL BLOCKING;
PSYCHOSIS;
SIDE EFFECT;
TREATMENT FAILURE;
TUBERCULOSIS;
VIRUS INFECTION;
|
|
EID: 4444384070
PISSN: 00316873
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (2)
|
